中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
25期
46-49
,共4页
结核,肺%复治%中药疗法%抗结核药
結覈,肺%複治%中藥療法%抗結覈藥
결핵,폐%복치%중약요법%항결핵약
Tuberculosis,pulmonary%Retreatment%Traditional Chinese drug theropy%Autitubercular agents
目的 探讨芪甲利肺胶囊辅助治疗复治涂阳肺结核的疗效及安全性.方法 将160例复治涂阳肺结核患者按人院先后顺序随机分为观察组和对照组,每组80例,所有患者均采用3SHRZE/6HRE方案抗结核治疗,观察组在此基础上加用芪甲利肺胶囊.比较两组痰菌阴转率、病灶显效率、空洞闭合率、细胞免疫功能及临床症状改善等方面的差异.结果 观察组和对照组分别有77例和78例患者完成试验;强化期结束时和疗程结束时观察组的痰菌阴转率[79.2％(61/77),92.2％(71/77)]高于对照组[64.1％(50/78),78.2％(61/78)],差异有统计学意义(P＜0.05);强化期结束时观察组的病灶有效率及空洞闭合率分别为74.0％ (57/77),26.0％ (20/77),均高于对照组的52.6％(41/78)和11.5％ (9/78),差异有统计学意义(P＜0.05);疗程结束时观察组的病灶有效率及空洞闭合率分别为92.2％(71/77),54.5％(42/77),均高于对照组的76.9％(60/78)和29.5％(23/78),差异有统计学意义(P＜0.05);治疗结束后观察组CD3+、CD4+、CD4+/CD8+明显高于对照组,差异有统计学意义(P＜0.05);观察组发热、咳嗽、咳痰、胸闷、胸痛症状缓解时间明显短于对照组,差异有统计学意义(P＜0.05).口服芪甲利肺胶囊的不良反应发生率为1.3％(1/77).结论 芪甲利肺胶囊辅助治疗复治涂阳肺结核能提高患者的细胞免疫功能,提高痰菌阴转率、病灶显效率及空洞闭合率,加快临床症状的缓解,临床用药较安全.
目的 探討芪甲利肺膠囊輔助治療複治塗暘肺結覈的療效及安全性.方法 將160例複治塗暘肺結覈患者按人院先後順序隨機分為觀察組和對照組,每組80例,所有患者均採用3SHRZE/6HRE方案抗結覈治療,觀察組在此基礎上加用芪甲利肺膠囊.比較兩組痰菌陰轉率、病竈顯效率、空洞閉閤率、細胞免疫功能及臨床癥狀改善等方麵的差異.結果 觀察組和對照組分彆有77例和78例患者完成試驗;彊化期結束時和療程結束時觀察組的痰菌陰轉率[79.2％(61/77),92.2％(71/77)]高于對照組[64.1％(50/78),78.2％(61/78)],差異有統計學意義(P＜0.05);彊化期結束時觀察組的病竈有效率及空洞閉閤率分彆為74.0％ (57/77),26.0％ (20/77),均高于對照組的52.6％(41/78)和11.5％ (9/78),差異有統計學意義(P＜0.05);療程結束時觀察組的病竈有效率及空洞閉閤率分彆為92.2％(71/77),54.5％(42/77),均高于對照組的76.9％(60/78)和29.5％(23/78),差異有統計學意義(P＜0.05);治療結束後觀察組CD3+、CD4+、CD4+/CD8+明顯高于對照組,差異有統計學意義(P＜0.05);觀察組髮熱、咳嗽、咳痰、胸悶、胸痛癥狀緩解時間明顯短于對照組,差異有統計學意義(P＜0.05).口服芪甲利肺膠囊的不良反應髮生率為1.3％(1/77).結論 芪甲利肺膠囊輔助治療複治塗暘肺結覈能提高患者的細胞免疫功能,提高痰菌陰轉率、病竈顯效率及空洞閉閤率,加快臨床癥狀的緩解,臨床用藥較安全.
목적 탐토기갑리폐효낭보조치료복치도양폐결핵적료효급안전성.방법 장160례복치도양폐결핵환자안인원선후순서수궤분위관찰조화대조조,매조80례,소유환자균채용3SHRZE/6HRE방안항결핵치료,관찰조재차기출상가용기갑리폐효낭.비교량조담균음전솔、병조현효솔、공동폐합솔、세포면역공능급림상증상개선등방면적차이.결과 관찰조화대조조분별유77례화78례환자완성시험;강화기결속시화료정결속시관찰조적담균음전솔[79.2％(61/77),92.2％(71/77)]고우대조조[64.1％(50/78),78.2％(61/78)],차이유통계학의의(P＜0.05);강화기결속시관찰조적병조유효솔급공동폐합솔분별위74.0％ (57/77),26.0％ (20/77),균고우대조조적52.6％(41/78)화11.5％ (9/78),차이유통계학의의(P＜0.05);료정결속시관찰조적병조유효솔급공동폐합솔분별위92.2％(71/77),54.5％(42/77),균고우대조조적76.9％(60/78)화29.5％(23/78),차이유통계학의의(P＜0.05);치료결속후관찰조CD3+、CD4+、CD4+/CD8+명현고우대조조,차이유통계학의의(P＜0.05);관찰조발열、해수、해담、흉민、흉통증상완해시간명현단우대조조,차이유통계학의의(P＜0.05).구복기갑리폐효낭적불량반응발생솔위1.3％(1/77).결론 기갑리폐효낭보조치료복치도양폐결핵능제고환자적세포면역공능,제고담균음전솔、병조현효솔급공동폐합솔,가쾌림상증상적완해,림상용약교안전.
Objective To evaluate the efficacy and safety of Qijialifei capsule,a kind of Chinese traditional medicine,as adjuvant chemotherapy for retreatment patients with smear positive pulmonary tuberculosis.Methods One hundred and sixty retreatment cases with smear positive pulmonary tuberculosis were divided into observation group (80 cases) and control group (80 cases).All patients received the therapy of 3SHRZE/6HRE.The patients in observation group took Qijialifei capsule.Then comparisons were made between two groups in the sputum tubercle bacillus conversion rate,focus improvement rate,cavity closing rate,the cellular immune function,and clinical symptom improvement.Results In 160 cases,77 cases in observation group and 78 cases in control group completed the treatment.At the end of intensified therapy period and at the end of the whole therapy the sputum tubercle bacillus conversion rate [79.2％ (61/77),92.2％ (71/77)] in observation group were significantly higher than those in control group [64.1％ (50/78),78.2％ (61/78)](P ＜ 0.05).The focus improvement rate,cavity closing rate in observation group [74.0％(57/77),26.0％(20/77)] were significantly higher than those in control group [52.6％ (41/78),11.5％ (9/78)] (P ＜ 0.05).At the end of intensified therapy period,the focus improvement rate,cavity closing rate in observation group [92.2％ (71/77),54.5％ (42/77)] were significandy higher than those in control group [76.9％ (60/78),29.5％ (23/78)] (P ＜ 0.05).By the end of the whole therapy,the number of CD3+,CD4+,CD4+/CD8+ of patients in observation group were significantly higher than those in control group (P ＜ 0.05).The disappearance of clinical symptoms in observation group was shorter than that in control group(P ＜ 0.05).The rate of side effects on Qijialifei capsule was only 1.3％(1/77).Conclusions Qijialifei capsule can improve the cellular immune function of the patients,can effectively alleviate the symptoms and can improve the sputum tubercle bacillus conversion rate,radiographic focus improvement rate and cavity closing rate.It is safe.
